Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Rocket Pharmaceuticals ( (RCKT) ).
On September 29, 2025, Pedro Granadillo resigned from the Board of Directors of Rocket Pharmaceuticals, effective September 30, 2025. His resignation was not due to any disagreements with the company’s operations, policies, or practices.
The most recent analyst rating on (RCKT) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on Rocket Pharmaceuticals stock, see the RCKT Stock Forecast page.
Spark’s Take on RCKT Stock
According to Spark, TipRanks’ AI Analyst, RCKT is a Underperform.
Rocket Pharmaceuticals’ overall score reflects its position as a biotechnology firm in the development phase, with significant financial risks due to its lack of revenue and reliance on external financing. Technical indicators suggest potential volatility, while the negative P/E ratio highlights current valuation challenges. The company’s strong equity position is a positive factor, but ongoing cash burn remains a critical concern.
To see Spark’s full report on RCKT stock, click here.
More about Rocket Pharmaceuticals
Average Trading Volume: 3,692,847
Technical Sentiment Signal: Sell
Current Market Cap: $341M
Learn more about RCKT stock on TipRanks’ Stock Analysis page.